CY1108051T1 - Συνθεση με βαση παραγωγα υποκατεστημενης 1,3-διφαινυλπροπ-2-εν-1-ονης - Google Patents

Συνθεση με βαση παραγωγα υποκατεστημενης 1,3-διφαινυλπροπ-2-εν-1-ονης

Info

Publication number
CY1108051T1
CY1108051T1 CY20071100879T CY071100879T CY1108051T1 CY 1108051 T1 CY1108051 T1 CY 1108051T1 CY 20071100879 T CY20071100879 T CY 20071100879T CY 071100879 T CY071100879 T CY 071100879T CY 1108051 T1 CY1108051 T1 CY 1108051T1
Authority
CY
Cyprus
Prior art keywords
compositions
diffinylpro
producers
composition
prevent
Prior art date
Application number
CY20071100879T
Other languages
English (en)
Inventor
Jamila Najib
Karine Caumont-Bertrand
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of CY1108051T1 publication Critical patent/CY1108051T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/055—Phenols the aromatic ring being substituted by halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/22—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers
    • C07C69/712—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Η παρούσα εφεύρεση αφορά συνθέσεις που περιλαμβάνουν τα παράγωγα υποκατεστημένης 1,3-διφαινυλπροπ-2-εν-1-όνης προορισμένα για θεραπευτική χρήση. Οι συνθέσεις της ο εφεύρεσης είναι χρησιμοποιήσιμες κυρίως για να αποτρέπονται ή να θεραπεύονται οι καρδιαγγειακές ασθένειες, το σύνδρομο Χ, η επαναστένωση, ο διαβήτης, η παχυσαρκία, η υπέρταση, οι φλεγμονώδεις ασθένειες, οι καρκίνοι ή νεοπλάσματα (καλοήθεις ή κακοήθεις όγκοι), οι νευροεκφυλιστικές ασθένειες, δερματολογικές και οι διαταραχές που σχετίζονται με το οξειδωτικό στρες, για να αποτρέπονται ή να θεραπεύονται τα αποτελέσματα γήρανσης γενικά και για παράδειγμα η γήρανση του δέρματος, κυρίως στο καλλυντικό πεδίο (η εμφάνιση ρυτίδων, κλπ.).
CY20071100879T 2002-07-08 2007-07-03 Συνθεση με βαση παραγωγα υποκατεστημενης 1,3-διφαινυλπροπ-2-εν-1-ονης CY1108051T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0208570A FR2841784B1 (fr) 2002-07-08 2002-07-08 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
EP03762750A EP1519908B1 (fr) 2002-07-08 2003-07-08 Composition a base de derives de 1,3-diphenylprop-2-en-1-one substitues, preparations et utilisations

Publications (1)

Publication Number Publication Date
CY1108051T1 true CY1108051T1 (el) 2013-09-04

Family

ID=29725282

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100879T CY1108051T1 (el) 2002-07-08 2007-07-03 Συνθεση με βαση παραγωγα υποκατεστημενης 1,3-διφαινυλπροπ-2-εν-1-ονης

Country Status (24)

Country Link
US (3) US7632870B2 (el)
EP (1) EP1519908B1 (el)
JP (1) JP4907083B2 (el)
KR (1) KR100947907B1 (el)
CN (1) CN1688532B (el)
AT (1) ATE364588T1 (el)
AU (1) AU2003264699B2 (el)
BR (1) BRPI0312399B8 (el)
CA (1) CA2490993C (el)
CY (1) CY1108051T1 (el)
DE (1) DE60314420T2 (el)
DK (1) DK1519908T3 (el)
EA (1) EA012699B1 (el)
ES (1) ES2287529T3 (el)
FR (1) FR2841784B1 (el)
IL (1) IL165454A (el)
MX (1) MXPA05000425A (el)
NO (1) NO334650B1 (el)
NZ (1) NZ538052A (el)
PL (1) PL207707B1 (el)
PT (1) PT1519908E (el)
SI (1) SI1519908T1 (el)
WO (1) WO2004005243A2 (el)
ZA (1) ZA200501081B (el)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2841784B1 (fr) 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
FR2841900B1 (fr) * 2002-07-08 2007-03-02 Genfit S A Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
BRPI0506718A (pt) * 2004-01-08 2007-05-02 Genfit compostos, processo de preparação dos mesmos, e, composição farmacêutica ou cosmética
RU2431634C2 (ru) 2005-03-11 2011-10-20 Говард Флори Инститьют Оф Експериментл Физиолоджи Энд Медсин Соединения флавоноидов и их применение
SI2641596T1 (sl) 2009-11-26 2018-09-28 Genfit Uporaba 1,3-difenilprop-2-en-1-on derivatov za zdravljenje motenj jeter
WO2011080276A1 (en) 2009-12-29 2011-07-07 Genfit Pharmaceutical combinations comprising a dpp-4 inhibitor and a 1,3-diphenylprop-2-en-1-one derivative
AR082138A1 (es) * 2010-07-12 2012-11-14 Hoffmann La Roche 1-hidroxiimino-3-fenil-propanos
WO2013012760A1 (en) 2011-07-15 2013-01-24 Numeta Sciences, Inc. Compositions and methods for modulating metabolic pathways
CA2851062A1 (en) * 2011-10-26 2013-05-02 F. Hoffmann-La Roche Ag 1-cycloalkyl- or 1-heterocyclyl-hydroxyimino-3-phenyl-propanes
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
CN108452311A (zh) 2012-11-13 2018-08-28 纽斯尔特科学公司 用于增强能量代谢的组合物和方法
EA031718B1 (ru) * 2013-01-18 2019-02-28 Женфит Лечение фиброза и рака, связанных с тирозинкиназой
SG11201507046UA (en) 2013-03-15 2015-10-29 Nusirt Sciences Inc Leucine and nicotinic acid reduces lipid levels
MX2016011063A (es) 2014-02-27 2016-11-30 Nusirt Sciences Inc Composiciones y metodos para la reduccion o prevencion de esteatosis hepatica.
US10442761B2 (en) 2016-02-16 2019-10-15 Concert Pharmaceuticals, Inc. Deuterated GFT-505
EA201892201A1 (ru) * 2016-03-30 2019-03-29 Женфит Неинвазивная диагностика неалкогольного стеатогепатита
KR20230156167A (ko) * 2016-04-16 2023-11-13 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 바큘로바이러스 시스템-생산된 재조합 아데노-연관 바이러스의 생물학적 효력을 증진시키는 방법
CN109316601B (zh) * 2017-07-31 2021-11-09 武汉朗来科技发展有限公司 药物组合物及其用途
CN108658908B (zh) * 2017-07-31 2019-05-10 广州必贝特医药技术有限公司 1，3-二取代烯酮类化合物及其应用
EP3719010B1 (en) 2017-11-30 2023-07-26 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Aromatic compound, pharmaceutical composition thereof and use thereof
TW202019870A (zh) 2018-08-03 2020-06-01 法商Ｇｅｎｆｉｔ公司 艾拉菲諾鹽
US11634387B2 (en) 2019-09-26 2023-04-25 Abionyx Pharma Sa Compounds useful for treating liver diseases
BR112022015807A2 (pt) 2020-02-10 2023-03-14 Genfit Polimorfos de elafibranor
WO2024029639A1 (ko) * 2022-08-02 2024-02-08 제이투에이치바이오텍 주식회사 3성분 프로드럭, 이의 약학적 조성물 및 의약 용도

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558612A (en) * 1968-05-22 1971-01-26 Dow Chemical Co Substituted phenoxyacetic acids
CH593224A5 (el) * 1973-10-30 1977-11-30 Taisho Pharmaceutical Co Ltd
US3994955A (en) 1975-01-20 1976-11-30 G. D. Searle & Co. Substituted phenoxydialkylacetic acids and esters
JPS5278856A (en) * 1975-12-26 1977-07-02 Taisho Pharmaceut Co Ltd Preparation of chalcone ethers
US4190671A (en) * 1977-03-17 1980-02-26 Biorex Laboratories Limited Chalcone derivatives
JPS5419947A (en) 1977-07-16 1979-02-15 Taisho Pharmaceut Co Ltd Chalcone derivatives
US4163859A (en) * 1977-07-18 1979-08-07 G. D. Searle & Co. Phenoxyldialkyl acetic acids and esters
GB8426424D0 (en) * 1984-10-19 1984-11-28 Biorex Laboratories Ltd Chalcone derivatives
JPS6310720A (ja) * 1986-07-01 1988-01-18 Nippon Kayaku Co Ltd ５−リポキシゲナ−ゼ阻害剤および抗アレルギ−剤
JPH023670A (ja) 1988-06-22 1990-01-09 Nippon Oil & Fats Co Ltd アルキルチオカルコン誘導体
JPH0742227B2 (ja) * 1988-11-25 1995-05-10 日本ハイポックス 腎臓疾患治療剤
US5731454A (en) * 1990-02-12 1998-03-24 Virginia Commonwealth University Allosteric modifiers of hemoglobin useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood
US5705521A (en) * 1990-02-12 1998-01-06 The Center For Innovative Technology Use of allosteric hemoglobin modifiers in combination with radiation therapy to treat carcinogenic tumors
JPH0442229A (ja) 1990-06-08 1992-02-12 Fujitsu Ltd レジスト材料およびパターンの形成方法
JPH05255655A (ja) * 1992-03-12 1993-10-05 Kanebo Ltd 紫外線吸収剤
JPH06122623A (ja) * 1992-10-09 1994-05-06 Minofuaagen Seiyaku Honpo:Goushi 抗腫瘍剤
US5276058A (en) * 1993-06-09 1994-01-04 Nippon Hypox Laboratories Incorporated 3,4-dihydroxychalcone derivatives
US5455270A (en) * 1993-08-11 1995-10-03 Bristol-Myers Squibb Co. Stabilized solutions of platinum(II) antitumor agents
DE4327365A1 (de) * 1993-08-14 1995-02-16 Boehringer Mannheim Gmbh Verwendung von Phenolen und Phenolderivaten als Arzneimittel mit fibrinogensenkender Wirkung
US5523302A (en) * 1993-11-24 1996-06-04 The Du Pont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
AU5474198A (en) 1996-12-24 1998-07-17 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
EP0947511A1 (en) 1998-03-30 1999-10-06 F. Hoffmann-La Roche Ag Derivatives of phenoxy acetic acid and of phenoxymethyl tetrazole having antitumor activity
CN1327384A (zh) * 1998-10-20 2001-12-19 韩国科学技术研究院 作为血浆高密度脂蛋白浓度增高剂的生物类黄酮
US7268160B2 (en) * 2000-01-27 2007-09-11 Takara Bio, Inc. Remedies
CA2413878A1 (en) * 2000-06-20 2001-12-27 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders
EP1254759B1 (de) 2001-05-03 2009-03-18 Leister Process Technologies Düse zum Schweissen von Kunststoffbahnen oder -folien
FR2841900B1 (fr) 2002-07-08 2007-03-02 Genfit S A Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
FR2841784B1 (fr) 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
FR2857361B1 (fr) * 2003-07-08 2005-09-09 Genfit S A PREPARATION DE DERIVES DE 1,3-DIPHENYPROP-2-¼n-1-one

Also Published As

Publication number Publication date
PT1519908E (pt) 2007-09-04
US20120129932A1 (en) 2012-05-24
CA2490993A1 (fr) 2004-01-15
DE60314420D1 (de) 2007-07-26
NO20045082L (no) 2004-12-27
PL373465A1 (en) 2005-09-05
US20050171149A1 (en) 2005-08-04
CA2490993C (fr) 2012-09-18
SI1519908T1 (sl) 2007-08-31
NO334650B1 (no) 2014-05-05
JP2005532386A (ja) 2005-10-27
MXPA05000425A (es) 2005-07-22
US8106097B2 (en) 2012-01-31
FR2841784A1 (fr) 2004-01-09
KR100947907B1 (ko) 2010-03-17
FR2841784B1 (fr) 2007-03-02
AU2003264699A1 (en) 2004-01-23
EA200500170A1 (ru) 2005-10-27
EP1519908A2 (fr) 2005-04-06
WO2004005243A3 (fr) 2004-04-22
ES2287529T3 (es) 2007-12-16
AU2003264699B2 (en) 2009-09-24
EP1519908B1 (fr) 2007-06-13
WO2004005243A2 (fr) 2004-01-15
PL207707B1 (pl) 2011-01-31
US8461212B2 (en) 2013-06-11
CN1688532A (zh) 2005-10-26
US7632870B2 (en) 2009-12-15
BRPI0312399B1 (pt) 2020-03-31
EA012699B1 (ru) 2009-12-30
KR20050019818A (ko) 2005-03-03
IL165454A (en) 2012-12-31
US20100120909A1 (en) 2010-05-13
ZA200501081B (en) 2007-04-25
BRPI0312399B8 (pt) 2021-05-25
DE60314420T2 (de) 2008-02-28
ATE364588T1 (de) 2007-07-15
IL165454A0 (en) 2006-01-15
DK1519908T3 (da) 2007-10-15
JP4907083B2 (ja) 2012-03-28
NZ538052A (en) 2007-09-28
CN1688532B (zh) 2012-07-11
BR0312399A (pt) 2005-04-12

Similar Documents

Publication Publication Date Title
CY1108051T1 (el) Συνθεση με βαση παραγωγα υποκατεστημενης 1,3-διφαινυλπροπ-2-εν-1-ονης
CY1108722T1 (el) Πολυκυκλικες ενωσεις και η χρηση τους ως αναστολεων των ενζυμων parp, vegfr2 και mlk3
CY1115730T1 (el) Θεραπευτικοι επιτοποι και χρησεις αυτων
CY1105078T1 (el) Ανταγωνιστες τεκ
CY1108274T1 (el) Μακροβιο ομοιαζον με γλυκογονο πεπτιδιο 2 (glp-2) για την θεραπεια γαστρεντερικων ασθενειων και διαταραχων
ATE447561T1 (de) Substituierte aryl 1,4-pyrazin derivate
CY1105821T1 (el) Τρικυκλικες ενωσεις
ATE508116T1 (de) Ionische uv-a-sonnenschutzmittel und zusammensetzungen, die diese enthalten
DE69731885D1 (de) Apoptose induzierende adamantyl-derivate und deren verwendung als antikrebsmittel
CY1106853T1 (el) Χρηση συζευγματων χολικου οξεος ή λιπαρου οξεος χολικου αλατος
CY1107475T1 (el) Αναστολεις ρο-κινασης
CY1107370T1 (el) Παραγωγα ινδανο οξεικου οξεος και χρηση αυτων σαν φαρμακευτικοι παραγοντες, ενδιαμεσα και μεθοδος παρασκευης
CY1115316T1 (el) Πεπτιδια για τη θεραπευτικη αγωγη βητα-αμυλοειδωσεων
CY1106526T1 (el) Παραγωγα ν-θειαζολ-2-υλο-βενζαμιδης
DE602005002562D1 (de) Pyrrolylsubstituierte pyridoä2,3-düpyrimidin-7-one und derivate davon als therapeutische mittel
DE60137307D1 (de) Substituierte sapogenine und ihre verwendung
CY1110113T1 (el) Φωσφολιπιδιου παραγωγα βαλπροϊκου οξεος και μειγματα αυτων
DE69911210D1 (de) Verwendung von piperin und derivate davon zur behandlung von hautpigmentierungstörungen und hautkrebs
CY1107116T1 (el) Νεες κυκλοεξυλ σουλφονες
CY1107485T1 (el) 3-θειομεθυλπυραζoλες ως παρασιτοκτoνα
ES2168463T3 (es) Derivados fenilicos trisustituidos.
EA200500244A1 (ru) Тетрапропиламмония тетратиомолибдат и родственные соединения для антиангиогенной терапии
TR199800270T1 (xx) Kanser hastal�klar�n�n ilerlemesini �nlemede flukonazol kullan�m�.
ATE411981T1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
ATE453408T1 (de) Farbstoff-sulfenate für die duale phototherapie